AstraZeneca Pharma India (NSE:ASTRAZEN) Other Long Term Assets: ₹0 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:ASTRAZEN AstraZeneca Pharma India Ltd NSE:ASTRAZEN
92 GF Score
Price ₹7,753.00
GF Value ₹11,377.91
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is AstraZeneca Pharma India Other Long Term Assets?

AstraZeneca Pharma India NSE:ASTRAZEN -0.51% 92 Other Long Term Assets is ₹0 Mil as of Jun. 2026. GuruFocus rates NSE:ASTRAZEN with a GF Score™ of 92/100 and a GF Value™ of ₹11,377.91 (Possible Value Trap). The stock has 6 warning signs investors should review.

AstraZeneca Pharma India's other long-term assets for the quarter that ended in Jun. 2026 was ₹0 Mil.

AstraZeneca Pharma India's quarterly other long-term assets increased from Dec. 2025 (₹0 Mil) to Mar. 2026 (₹1,317 Mil) but then stayed the same from Mar. 2026 (₹1,317 Mil) to Jun. 2026 (₹0 Mil).

AstraZeneca Pharma India's annual other long-term assets increased from Mar. 2024 (₹784 Mil) to Mar. 2025 (₹1,115 Mil) and increased from Mar. 2025 (₹1,115 Mil) to Mar. 2026 (₹1,317 Mil).

AstraZeneca Pharma India Other Long Term Assets Historical Data

* Premium members only.

The historical data trend for AstraZeneca Pharma India's Other Long Term Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AstraZeneca Pharma India Other Long Term Assets Chart

AstraZeneca Pharma India Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Other Long Term Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 742.00 792.10 783.70 1,115.20 1,317.00

AstraZeneca Pharma India Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Other Long Term Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 1,192.40 0.00 1,317.00 0.00
NSE:ASTRAZEN
92GF Score
AstraZeneca Pharma India Ltd NSE:ASTRAZEN
Other Long Term Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

AstraZeneca Pharma India Other Long Term Assets Calculation

GuruFocus lists Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets under the "Total Long-Term Assets" section.

Other Long Term Assets includes following items:
Investment in Properties
Non-current Accounts Receivable
Non-current Note Receivables
Non-current Deferred Assets
Non-current Prepaid Assets
Defined Pension Benefit
Other (too numerous to list)
Some companies can do choose to report each of these items separately. Yet, there are a variety of Other Long Term Assets which are simply too numerous to list.

Frequently Asked Questions Learn more about Other Long Term Assets →
What does a Other Long Term Assets of ₹0 Mil mean?
AstraZeneca Pharma India (NSE:ASTRAZEN) has a Other Long Term Assets of ₹0 Mil as of Jun. 2026. Other long-term assets as record on a company's balance sheet not categorized as standard assets. View historical data on AstraZeneca Pharma India and its competitors.
Is AstraZeneca Pharma India's Other Long Term Assets too high?
AstraZeneca Pharma India's current Other Long Term Assets is ₹0 Mil. Overall, AstraZeneca Pharma India has a GF Score™ of 92/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does AstraZeneca Pharma India's Other Long Term Assets compare to ZTS?
AstraZeneca Pharma India's Other Long Term Assets of ₹0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Long Term Assets for a Drug Manufacturers company?
A good Other Long Term Assets depends on the Drug Manufacturers industry context. However, Other Long Term Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Long Term Assets mean?
A high Other Long Term Assets can signal that a stock is expensive relative to its fundamentals. Other long-term assets as record on a company's balance sheet not categorized as standard assets. View historical data on AstraZeneca Pharma India and its competitors. AstraZeneca Pharma India's current Other Long Term Assets is ₹0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AstraZeneca Pharma India stock overvalued right now?
Based on GuruFocus' analysis, AstraZeneca Pharma India (NSE:ASTRAZEN) is currently considered Possible Value Trap. The stock's GF Value™ is ₹11,377.91, compared to a current price of ₹7,753.00 — trading 31.9% below its estimated fair value. The current Other Long Term Assets is ₹0 Mil. AstraZeneca Pharma India's overall GF Score™ is 92/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Long Term Assets calculated?
Other Long Term Assets is calculated from a company's financial statements. For AstraZeneca Pharma India (NSE:ASTRAZEN), the current Other Long Term Assets is ₹0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is AstraZeneca Pharma India (NSE:ASTRAZEN) Overvalued in 2026?

Based on GuruFocus' analysis, AstraZeneca Pharma India stock appears to be undervalued. The current stock price of ₹7,753.00 is trading 31.9% below its estimated GF Value™ of ₹11,377.91. GuruFocus considers AstraZeneca Pharma India to be Possible Value Trap.

Key valuation signals for NSE:ASTRAZEN:

  • Other Long Term Assets: ₹0 Mil
  • GF Value™: ₹11,377.91 vs. price of ₹7,753.00 (31.9% below fair value)
  • GF Score™: 92/100 with 6 warning signs

No single metric tells the full story. See the NSE:ASTRAZEN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

AstraZeneca Pharma India Business Description

Other Exchanges 506820:India
Address Outer Ring Road, Block N1, 12th Floor, Manyata Embassy Business Park, Rachenahalli, Bangalore, KA, IND, 560 045
AstraZeneca Pharma India Ltd is engaged in the manufacture, trading, and marketing of pharmaceutical products. Its only operating segment is Healthcare. The company generates revenue from the sale of products such as Tablets, Injectables, and Inhalation. Geographically, it derives a majority of its revenue from India. It focuses on areas such as Cardiovascular, Renal and Metabolism (CVRM), Oncology, Respiratory, Inflammation, Autoimmunity, Neuroscience Infection and Vaccines. The company operates within India, and outside, like Cambridge, Gothenburg, and Gaithersburg. The majority of revenue is from India.
92GF Score

Get the complete analysis for NSE:ASTRAZEN

Other Long Term Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹7,753.00
Price
₹11,377.91
GF Value